Pluri Inc
NASDAQ:PLUR

Watchlist Manager
Pluri Inc Logo
Pluri Inc
NASDAQ:PLUR
Watchlist
Price: 4.58 USD -4.98% Market Closed
Market Cap: 25.5m USD
Have any thoughts about
Pluri Inc?
Write Note

Pluri Inc
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pluri Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Pluri Inc
NASDAQ:PLUR
Pre-Tax Income
-$22.3m
CAGR 3-Years
25%
CAGR 5-Years
8%
CAGR 10-Years
2%
Collplant Biotechnologies Ltd
NASDAQ:CLGN
Pre-Tax Income
-$7m
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Pre-Tax Income
$15.9m
CAGR 3-Years
62%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Pre-Tax Income
-$111.3m
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Pre-Tax Income
-$7.2m
CAGR 3-Years
28%
CAGR 5-Years
6%
CAGR 10-Years
N/A
B
Bonus Biogroup Ltd
TASE:BONS
Pre-Tax Income
-â‚Ş29.2m
CAGR 3-Years
26%
CAGR 5-Years
-5%
CAGR 10-Years
-9%
No Stocks Found

Pluri Inc
Glance View

Market Cap
25.2m USD
Industry
Biotechnology

Pluri Inc is a IL-based company operating in Biotechnology industry. Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The firm's products include PLX-PAD and PLX R18. The firm's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The firm's PLX products are administered using a standard needle and syringe. The firm's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

PLUR Intrinsic Value
1.42 USD
Overvaluation 69%
Intrinsic Value
Price

See Also

What is Pluri Inc's Pre-Tax Income?
Pre-Tax Income
-22.3m USD

Based on the financial report for Sep 30, 2024, Pluri Inc's Pre-Tax Income amounts to -22.3m USD.

What is Pluri Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
2%

Over the last year, the Pre-Tax Income growth was 20%. The average annual Pre-Tax Income growth rates for Pluri Inc have been 25% over the past three years , 8% over the past five years , and 2% over the past ten years .

Back to Top